Investing.com - Can Fite Biopharma ADR reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Can Fite Biopharma ADR announced earnings per share of $-0.135 on revenue of $215K. Analysts polled by Investing.com anticipated EPS of $-0.155 on revenue of $220K.
Can Fite Biopharma ADR shares are up 7% from the beginning of the year, still down 57.18% from its 52 week high of $4.39 set on March 16. They are under-performing the CAC 40 which is up 20.08% from the start of the year.
Can Fite Biopharma ADR shares gained 1.62% in intra-day trade following the report.
Can Fite Biopharma ADR follows other major Healthcare sector earnings this month
Can Fite Biopharma ADR's report follows an earnings beat by Merck ADR on August 5, who reported EPS of $0.5304 on revenue of $5.77B, compared to forecasts EPS of $0.4897 on revenue of $5.63B.
Hoya Corp had beat expectations on July 29 with second quarter EPS of $1.02 on revenue of $1.44B, compared to forecast for EPS of $0.8576 on revenue of $1.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar